Business Context and Reporting Period
This Form 8-K is a current report filed by Fluidigm Corporation (not Standard BioTools Inc.) on October 30, 2018. The filing reports the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and director compensation.
Material Changes
The Board of Directors increased its size from six to seven members. Laura Clague, C.P.A., was appointed as a Class III director and a member of the audit committee, effective immediately on October 30, 2018.
Guidance, Outlook, and Compensation Details
Ms. Clague's appointment includes the following compensatory arrangements:
- Cash Compensation: Base annual retainer of $40,000 plus $10,000 for audit committee service.
- Initial Equity Grant: Option to purchase 15,000 shares of common stock and 10,000 restricted stock units (RSUs).
- Vesting Schedule: Initial awards vest 25% annually on the grant anniversary, contingent on continued service.
- Future Eligibility: Beginning in 2019, she will be eligible for annual grants of 10,600 stock options and 6,100 RSUs.
The filing incorporates a press release dated October 31, 2018, and a standard indemnification agreement.
Investor Verification Checklist
- Verify the exact vesting terms and exercise price of the 15,000 stock options granted to Ms. Clague.
- Confirm the total number of shares authorized under the 2011 Equity Incentive Plan to assess dilution impact.
- Review the attached press release (Exhibit 99.1) for additional biographical details on the new director.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.